These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 22773665)
21. Role of ursolic acid chalcone, a synthetic analogue of ursolic acid, in inhibiting the properties of CD133(+) sphere-forming cells in liver stem cells. Lin RX; Gong LL; Fan LM; Zhao ZK; Yang SL Int J Clin Exp Pathol; 2015; 8(2):1427-34. PubMed ID: 25973027 [TBL] [Abstract][Full Text] [Related]
22. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273 [TBL] [Abstract][Full Text] [Related]
23. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805 [TBL] [Abstract][Full Text] [Related]
24. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609 [TBL] [Abstract][Full Text] [Related]
26. Arsenite inhibits the function of CD133 Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564 [TBL] [Abstract][Full Text] [Related]
27. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042 [TBL] [Abstract][Full Text] [Related]
28. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma. Yan M; Li H; Zhu M; Zhao F; Zhang L; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J PLoS One; 2013; 8(4):e61056. PubMed ID: 23593389 [TBL] [Abstract][Full Text] [Related]
29. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Zhang L; Zhang L; Li H; Ge C; Zhao F; Tian H; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Sci Rep; 2016 Jun; 6():27426. PubMed ID: 27255419 [TBL] [Abstract][Full Text] [Related]
30. CD133 Liu K; Hao M; Ouyang Y; Zheng J; Chen D Sci Rep; 2017 Jan; 7():41499. PubMed ID: 28134312 [TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225 [TBL] [Abstract][Full Text] [Related]
32. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Yilmaz G; Akyol G; Cakir A; Ilhan M Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884 [TBL] [Abstract][Full Text] [Related]
33. Biology and clinical implications of CD133(+) liver cancer stem cells. Ma S Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864 [TBL] [Abstract][Full Text] [Related]
34. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902 [TBL] [Abstract][Full Text] [Related]
35. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122 [TBL] [Abstract][Full Text] [Related]
36. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Chai S; Tong M; Ng KY; Kwan PS; Chan YP; Fung TM; Lee TK; Wong N; Xie D; Yuan YF; Guan XY; Ma S Oncotarget; 2014 Jul; 5(14):5725-35. PubMed ID: 25015418 [TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. Maegdefrau U; Amann T; Winklmeier A; Braig S; Schubert T; Weiss TS; Schardt K; Warnecke C; Hellerbrand C; Bosserhoff AK J Pathol; 2009 Aug; 218(4):520-9. PubMed ID: 19431154 [TBL] [Abstract][Full Text] [Related]
38. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077 [TBL] [Abstract][Full Text] [Related]
39. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482 [TBL] [Abstract][Full Text] [Related]
40. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Ding K; Liao Y; Gong D; Zhao X; Ji W Biochem Biophys Res Commun; 2018 Jul; 502(2):194-201. PubMed ID: 29800569 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]